Alector (ALEC)

Executive Summary

Alector is a clinical-stage biopharmaceutical company pioneering immuno-neurology, leveraging the immune system to treat neurodegenerative diseases. Its pipeline includes monoclonal antibodies targeting Alzheimer's disease (AD), frontotemporal dementia (FTD), and other conditions. The company's lead candidate, AL001, showed promise in FTD but a Phase 3 trial was terminated, raising uncertainties. Alector's partnered program with GSK, GSK4527226 (formerly AL002? Actually GSK4527226 is a separate anti-TREM2 antibody), is currently in Phase 2 for Alzheimer's disease, with two ongoing trials—one expected to complete in late 2026 and another recruiting through 2028. The company's valuation (~$238M) reflects its high-risk, high-reward profile amidst setbacks and ongoing development. Alector's ability to generate positive data from its GSK partnership is critical for near-term value inflection.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 data readout for GSK4527226 in Alzheimer's Disease (NCT06079190)40% success
• TBDPotential strategic update or partnership following pipeline reprioritization50% success